Ingavirin capsules 60mg N7 children
Condition: New product
999 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Imidazolyl ethanamide pentanedioic acid
Release form
Capsules
Composition
In 1 capsule: Imidazolyl ethanamide pentanedioic acid (vitaglutam) 60 mg. Excipients: lactose monohydrate - 60 mg, potato starch - 23.72 mg, colloidal silicon dioxide (aerosil) - 1.47 mg, magnesium stearate - 1.47 mg.
Pharmacological effect
Ingavirin is an antiviral anti-inflammatory agent. Inghavirin has antiviral effect, is effective against influenza A viruses (A / H1 N1, including “swine” A / H1 N1 swl, A / H3N2, A / H5N1), type B, adenovirus infection, parainfluenza, respiratory syncytial infection. The antiviral mechanism of action is associated with the suppression of viral reproduction during the nuclear phase, the delayed migration of the newly synthesized NP virus from the cytoplasm into the nucleus. It has a modulating effect on the functional activity of the interferon system: causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced a-interferon-producing ability of blood leukocytes, stimulates the u-interferon-producing capacity of leukocytes. cells with high killer activity against viral-transformed cells and pronounced antiviral activity. The anti-inflammatory effect of Ingavirin is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-a), interleukins (IL-1B and IL-6)), a decrease in myeloperoxidase activity. Therapeutic efficacy in influenza and other acute respiratory viral infections (ARVI) is manifested in shortening the period of fever, reducing intoxication (headache, weakness, dizziness), catarrhal phenomena, reducing the number of complications and the duration of the disease as a whole. Experimental toxicological studies have shown a low toxicity level and a high safety profile of the drug (LD50 is more than 3000 times the therapeutic dose). The drug does not have mutagenic, immunotoxic, allergenic and carcinogenic properties, and has no local irritating effect.IngavirinR does not affect reproductive function, does not have embryotoxic and teratogenic effects.
Pharmacokinetics
Suction and distribution. At the recommended doses, the determination of the drug in the blood plasma using available techniques is not possible. In an experiment using a radioactive label, it was established that the drug rapidly enters the blood from the gastrointestinal tract. Evenly distributed throughout the internal organs. Cmax in the blood plasma and most organs is reached 30 minutes after the administration of the drug. The AUC values for the kidneys, liver and lungs slightly exceed the blood AUC (43.77 mcg · h / ml). AUC values for spleen, adrenal glands, lymph nodes and thymus are lower than blood AUC. MRT (average drug retention time) in the blood is 37.2 hours. When taking the drug for the course, the drug accumulates in the internal organs and tissues once a day. At the same time, the qualitative characteristics of the pharmacokinetic curves after each injection of the drug were identical: a rapid increase in the concentration of the drug after each injection 0.5–1 h after administration and then a slow decrease to 24 hours. Metabolism. The drug is not metabolized in the body and is excreted unchanged. Excretion. The main excretion process takes place within 24 hours. During this period, 80% of the administered dose is excreted: 34.8% is excreted in the time interval from 0 to 5 hours and 45.2% in the time interval from 5 to 24 hours. 77 are excreted through the intestine % of the drug and 23% through the kidneys.
Indications
Treatment and prevention of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection).
Contraindications
Individual intolerance to the components of the drug, pregnancy, children's age up to 7 years.
Use during pregnancy and lactation
The use of the drug during pregnancy has not been studied. The use of the drug during lactation has not been studied, therefore, if necessary, the use of the drug during lactation should stop breastfeeding.
Dosage and administration
Inside. Regardless of food intake. For the treatment of influenza and acute respiratory viral infections, children from 7 to 17 years old are prescribed 1 capsule (60 mg) once a day. The duration of treatment is 5-7 days (depending on the severity of the condition).The drug intake is started from the moment the first symptoms of the disease appear, preferably not later than 2 days from the onset of the disease.
Side effects
Allergic reactions (rare).
Overdose
Cases of drug overdose are not described.
Interaction with other drugs
The simultaneous use of Ingavirin with other antiviral drugs is not recommended. There were no cases of Ingavirin interaction with other drugs.
special instructions
The drug does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in people of various professions, including requiring increased attention and coordination of movements. It is not recommended to take other antiviral drugs at the same time.